All In Biotech

Drug Trial Radar · NCT02627963

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

May 24, 2016

Primary completion

Oct 4, 2018

Study completion Jun 21, 2021

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC). Participants will be randomized (1:1) to treatment with tivozanib or sorafenib. Participants will be stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category (favorable; intermediate; poor) and prior therapy (two prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI); a prior checkpoint inhibitor \[programmed cell death -1 protein (PD-1) or PD-1 ligand (PD1-L) inhibitor\] plus a prior VEGFR TKI; a prior VEGFR TKI plus any other systemic agent). All participants will be evaluated for progression free survival, overall survival, objective response rate, and the duration of response as well as safety and tolerability. Pharmacokinetic (PK) analyses are also included in study.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • Tivozanib hydrochlorideDrug

    Tivozanib hydrochloride

  • SorafenibDrug

    Sorafenib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks (up to approximately 5 years)

Locations

191 sites in 12 countries. Site status is shown where the registry gives one.

  • University Of UA Cancer Center(UACC)/DH-SJHMC

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Phoenix, Arizona

  • Arizona Oncology - Phoenix - Deer Valley Women's Center Loca

    Phoenix, Arizona

  • Arizona Oncology - Scottsdale

    Scottsdale, Arizona

  • City of Hope Comprehensive Breast Cancer Center

    Duarte, California

  • Long Beach Memorial Medical Center

    Fountain Valley, California

  • Marin Cancer Care

    Greenbrae, California

  • UCLA

    Los Angeles, California

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • Investigative Clinical Research of Indiana

    Indianapolis, Indiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Midwest Cancer Center

    Omaha, Nebraska

  • Urology Cancer Center, PC

    Omaha, Nebraska

  • Comprehensive Cancer Center Of Nevada

    Henderson, Nevada

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Comprehensive Cancer Center Of Nevada

    Las Vegas, Nevada

  • Comprehensive Cancer Center of Nevada

    Las Vegas, Nevada

  • Hackensack University Medical Center - John Theurer Cancer

    Hackensack, New Jersey

  • New York Oncology Hematology, P.C.

    Albany, New York

  • New York Oncology Hematology, PC

    Albany, New York

  • New York Oncology Hematology, P.C.

    Clifton Park, New York

  • New York Presbyterian Hospital

    New York, New York

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Wake Forest University Baptist Medical Center (WFUBMC)

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio Cancer Specialists

    Mansfield, Ohio

  • North Coast Cancer Care, Inc

    Sandusky, Ohio

  • Wooster Specialty and Surgery Center

    Wooster, Ohio

  • St. Luke University Health Network

    Easton, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania

  • Texas Oncology - Austin Midtown

    Austin, Texas

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.